Pfizer is a global biopharmaceutical company that researches, develops, and sells medicines and vaccines used in many therapeutic areas, including oncology, immunology, neurology, inflammation, and infectious disease. This overview focuses on prescription medications and vaccines that are approved and publicly available as of 2024, describing their primary medical uses and the conditions they address. It also highlights Pfizer’s ongoing clinical research to illustrate how its pipeline may influence future treatment options. Because product portfolios can change with new approvals, discontinuations, and regulatory updates, this summary reflects the current state of known authorized therapies linked to the Pfizer name.
Key prescription medicines and vaccines
Among the most widely recognized Pfizer therapies are treatments for cancer, autoimmune and inflammatory conditions, and vaccines that protect against infectious diseases. Below are representative products tied to the Pfizer name, along with their main clinical uses and development context.
Oncology and hematology
In cancer care, Pfizer’s medicines target specific molecular alterations or disease phases. These treatments are typically prescribed by medical oncology teams and are often part of combination regimens or sequential lines of therapy. The table below summarizes notable oncology and hematology assets linked to Pfizer with their principal indications and regulatory milestones.
| Asset (brand/generic) | Condition or indication | Approval and key regulatory milestones | Typical use in care |
|---|---|
| Ibrance (palbociclib) | Breast cancer | FDA approval 2015; used with endocrine therapy in hormone receptor-positive, HER2-negative breast cancer |
| Xtandi (enzalutamide) | Prostate cancer | FDA approval 2012; typically reserved for metastatic castration-resistant prostate cancer |
| Tukysa (tucatinib) | HER2-positive breast cancer | FDA approval 2020; used in combination with trastuzumab and capecitabine for HER2-positive disease |
| Braftovi (encorafenib) + Mektovi (binimetinib) | Melanoma, colorectal cancer | FDA approval for melanoma 2018; used in BRAF V600E-positive melanoma and certain colorectal cancer regimens |
| Xospata (gilteritinib) | Acute myeloid leukemia (FLT3-mutated) | FDA approval 2018; for FLT3-mutated relapsed or refractory acute myeloid leukemia |
| Vejulla (momelotinib) | Myelofibrosis | FDA approval 2023; reduces spleen size and improves anemia in adults with myelofibrosis |
| Daxdius (daxorubicin) | Acute myeloid leukemia | FDA approval 2023; used in newly eligible adults with AML |
Autoimmune and inflammatory conditions
Immunology and inflammation medicines from Pfizer are used to manage chronic autoimmune diseases by targeting specific components of the immune response. These treatments are typically introduced when disease activity is moderate to severe and when response to conventional therapies is insufficient. Key products include:
- Xeljanz (tofacitinib) — a Janus kinase (JAK) inhibitor for moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
- Otezla (apremilast) — a phosphodiesterase 4 inhibitor for plaque psoriasis, psoriatic arthritis, and oral ulcers in Behçet’s disease.
- Rinvoq (upadacitinib) — a JAK inhibitor indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and atopic dermatitis.
- Cibinqo (abrocitinib) — a Janus kinase inhibitor for moderate to severe atopic dermatitis.
- Enbrel (etanercept) — a tumor necrosis factor (TNF) inhibitor originally developed and commercialized with Amgen; used in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory conditions.
Neurology and pain
Neurological therapies within the Pfizer portfolio address movement disorders and certain pain conditions, often as part of comprehensive care plans guided by specialists.
- Comtan (entacapone) — a catechol-O-methyltransferase (COMT) inhibitor used with levodopa/carbidopa to manage motor fluctuations in Parkinson’s disease.
Vaccines and prophylactic public health products
Vaccines are central to Pfizer’s public health impact, with widely deployed products that protect individuals and communities from serious infectious diseases. Key vaccines currently associated with the Pfizer name include:
- Comirnaty (COVID-19 vaccine) — an mRNA vaccine authorized for prevention of coronavirus disease 2019; formulations updated to reflect circulating variants over time.
- Prevnar (pneumococcal conjugate vaccine) — helps protect against invasive pneumococcal disease and pneumonia caused by specific pneumococcal serotypes.
- Neulasta (pegfilgrastim) — used to help reduce the incidence of infection in patients with non-myeloid cancers receiving certain myelosuppressive anticancer drugs; technically a biologic but often linked with Pfizer’s portfolio.
- Vaccines under development for respiratory syncytial virus (RSV) and other emerging infectious diseases, with clinical trials ongoing to assess efficacy and safety.
How Pfizer medicines reach patients
For a medicine to reach patients, it must complete clinical development, submit evidence to regulatory authorities, and obtain marketing authorization. This process typically involves Phase I, II, and III trials, followed by regulatory review and, where appropriate, post-authorization studies. Some therapies receive accelerated or conditional approval based on early data, with further confirmatory studies required subsequently. After approval, pricing, reimbursement negotiations, and formulary placement determine real-world access. Continued pharmacovigilance monitors long-term safety and effectiveness once products are in widespread use.
Pipeline and clinical research context
Beyond currently marketed products, Pfizer maintains a robust pipeline spanning oncology, vaccines, anti-infectives, and rare diseases. Many candidates are in Phase II or Phase III evaluation, assessing efficacy, safety, dosing, and patient-reported outcomes. The progression of these assets may expand treatment options for areas with high unmet medical need. However, pipeline advancement does not guarantee approval; outcomes depend on trial results, regulatory assessments, and evolving health technology evaluation in different countries.
Reliable sources and further reading
For authoritative information on individual Pfizer medicines, including full prescribing details and current labels, consult official regulatory resources and the company’s public materials. Independent medical guidelines and national medicines agencies can provide additional context on appropriate use and reimbursement.
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Major therapy areas | Oncology, immunology/inflammation, neurology, infectious disease | Company disclosures |
| Representative oncology products | Ibrance, Xtandi, Tukysa, Braftovi/Mektovi, Xospata, Vejulla, Daxdius | Regulatory filings |
| Representative immunology products | Xeljanz, Otezla, Rinvoq, Cibinqo, Enbrel | Regulatory filings |
| Key vaccine products | Comirnaty (COVID-19), Prevnar (pneumococcal) | Regulatory filings |
| Clinical development approach | Phase I–III trials, regulatory submissions, post-authorization studies | Public regulatory documents |
Considerations and limitations
This overview reflects publicly available information as of 2024 and does not constitute medical or legal advice. Product availability, labeling, and indications can change due to new approvals, safety updates, or local regulatory decisions. Always consult a qualified healthcare professional for personal treatment decisions and refer to official prescribing information for any medicine referenced here. Details of pipeline assets are subject to development and regulatory outcomes that may not be realized.
Tags: pfizer medications, pfizer drugs, pfizer vaccines